Stock 002365 QIANJIANG YONGAN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Qianjiang Yongan Pharmaceutical Co., Ltd.

Equities

002365

CNE100000LZ9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-20 pm EDT 		5-day change 1st Jan Change
8.3 CNY +3.23% Intraday chart for Qianjiang Yongan Pharmaceutical Co., Ltd. +2.47% -15.13%
Apr. 29 Qianjiang Yongan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 80 million worth of its shares. CI
Apr. 29 Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 3,076 2,906 2,689 3,122 3,094 2,882
Enterprise Value (EV) 1 2,609 2,407 2,063 2,595 2,302 1,936
P/E ratio 17 x 31.7 x 25.6 x 28.2 x 22 x -234 x
Yield 0.96% 1.52% 1.07% - 0.95% 1.02%
Capitalization / Revenue 3.06 x 2.12 x 2.29 x 1.99 x 2.12 x 2.96 x
EV / Revenue 2.6 x 1.76 x 1.76 x 1.66 x 1.57 x 1.99 x
EV / EBITDA 9.69 x 10.7 x 8.58 x 10.8 x 7.85 x 12.2 x
EV / FCF -114 x 5.46 x 42.1 x -936 x 11 x 14.1 x
FCF Yield -0.87% 18.3% 2.38% -0.11% 9.06% 7.08%
Price to Book 1.95 x 1.76 x 1.57 x 1.68 x 1.53 x 1.45 x
Nbr of stocks (in thousands) 294,683 294,683 286,694 294,283 294,683 294,683
Reference price 2 10.44 9.860 9.380 10.61 10.50 9.780
Announcement Date 3/27/19 4/27/20 3/30/21 3/24/22 3/29/23 4/18/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,005 1,370 1,173 1,565 1,462 972.9
EBITDA 1 269.3 225.9 240.6 240.6 293.2 159
EBIT 1 189.6 113.3 127.7 124.8 169.8 23.97
Operating Margin 18.86% 8.27% 10.88% 7.97% 11.61% 2.46%
Earnings before Tax (EBT) 1 212.1 116.4 130.6 129.9 153.1 6.052
Net income 1 178.6 89.93 105.6 111.4 140.3 -12.31
Net margin 17.76% 6.56% 9% 7.12% 9.6% -1.27%
EPS 2 0.6135 0.3109 0.3659 0.3760 0.4762 -0.0418
Free Cash Flow 1 -22.82 440.6 49.04 -2.774 208.5 137.1
FCF margin -2.27% 32.15% 4.18% -0.18% 14.26% 14.09%
FCF Conversion (EBITDA) - 195.01% 20.39% - 71.12% 86.24%
FCF Conversion (Net income) - 489.87% 46.46% - 148.58% -
Dividend per Share 2 0.1007 0.1500 0.1000 - 0.1000 0.1000
Announcement Date 3/27/19 4/27/20 3/30/21 3/24/22 3/29/23 4/18/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 467 499 626 527 792 946
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -22.8 441 49 -2.77 209 137
ROE (net income / shareholders' equity) 12.1% 6.55% 6.84% 6.31% 6.54% -1.37%
ROA (Net income/ Total Assets) 6.76% 3.69% 3.92% 3.51% 4.51% 0.63%
Assets 1 2,644 2,436 2,694 3,178 3,115 -1,961
Book Value Per Share 2 5.360 5.620 5.970 6.330 6.850 6.730
Cash Flow per Share 2 0.0800 0.4100 0.3900 0.3200 0.9300 1.110
Capex 1 269 134 104 63 149 121
Capex / Sales 26.8% 9.81% 8.9% 4.03% 10.19% 12.41%
Announcement Date 3/27/19 4/27/20 3/30/21 3/24/22 3/29/23 4/18/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
QIANJIANG YONGAN PHARMACEUTICAL CO., LTD. Stock Qianjiang Yongan Pharmaceutical Co., Ltd.
-15.13% 338M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+37.78% 723B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.82% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.51% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.94% 331B
ABBVIE INC. Stock AbbVie Inc.
+5.14% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.64% 244B
ROCHE HOLDING AG Stock Roche Holding AG
-4.13% 208B
NOVARTIS AG Stock Novartis AG
+10.63% 210B
AMGEN INC. Stock Amgen Inc.
+9.32% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002365 Stock
  4. Financials Qianjiang Yongan Pharmaceutical Co., Ltd.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW